Thulium Laser and Growth Factors for Androgenetic Alopecia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Thulium laser + growth factor serum + LED, Thulium laser + growth factor serum, Thulium laser.
- Who it may be relevant to
- Registry conditions: Androgenetic Alopecia (AGA). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Germany
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Thulium Laser and Growth Factors for Androgenetic Alopecia - a Prospective, Clinical Study
Overview
Androgenetic alopecia (AGA) is a common cause of hair loss worldwide. It mainly affects the frontal and parietal regions of the scalp in up to 70 % of men and 40 % of women and has a significant negative psychological and emotional impact on those affected. Various therapies are currently approved for the treatment of AGA in men and women, including topical minoxidil, topical or systemic finasteride, platelet-rich plasma and hair transplantation. In addition to these pharmacological and surgical interventions, laser therapies including thulium laser with growth factors have gained popularity. Despite the clinical use of the thulium laser with growth factors in combination with LED phototherapy, there are only a few studies to date that have adequately investigated the objective and patient-side benefits of this therapy.
Interventions
- Procedure Thulium laser + growth factor serum + LED
3 sessions at intervals of 6 weeks - Procedure Thulium laser + growth factor serum
3 sessions at intervals of 6 weeks - Procedure Thulium laser
3 sessions at intervals of 6 weeks
Primary outcome measures
- Subject Global Aesthetic Improvement Scale [Time frame: 1 and 6 months post-treatment]
- Hair density [Time frame: at baseline, and 1 and 6 months post-treatment]
- hair thickness [Time frame: at baseline, and 1 and 6 months post-treatment]
Secondary outcome measures (1)
- pain intensity [Time frame: Periprocedural]
Eligibility criteria
Inclusion criteria
- Men and women aged 18 and over
- Good general health, no relevant previous illnesses
- Presence of an AGA
- Cognitive ability and willingness to give consent (informed consent)
- Be willing and able to attend follow-up visits
Exclusion criteria
- Age < 18 years
- Pregnant or breastfeeding women
- Scarring alopecia, alopecia due to dermatoses (e.g. lichen ruber, lupus erythemodes,...), alopecia due to chemical or physical noxae, and other non-AGAs
- Significant scarring of the region to be treated
- Significant open wounds or lesions in the region to be treated
- Metallic implants in the head region
- Mental illnesses (psychoses, body perception disorders)
- Use of isotretinoin or other retinoids, psychotropic drugs, coumarins or heparins in the last 2 weeks
- Resurfacing (fractional, ablative, non-ablative) of the affected region < 2 months before and during the study period
- Tendency to excessive scarring
- Lack of informed consent and/or data protection declarations
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Germany · 1 center
- University Medical Center Hamburg-Eppendorf — Hamburg
Identifiers
NCT: NCT07079657 · 04-23